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Abstract
Evaluating the activity of the complement system under conditions of altered thyroid hormone levels might help elucidate the 
role of complement in triggering autoimmune processes. Here, we investigated alternative pathway (AP) activity in male Wistar 
rats (180 ± 10 g) after altering their thyroid hormone levels by treatment with triiodothyronine (T3), propylthiouracil (PTU) or 
thyroidectomy. T3 and thyroxine (T4) levels were determined by chemiluminescence assays. Hemolytic assays were performed 
to evaluate the lytic activity of the AP. Factor B activity was evaluated using factor B-deficient serum. An anti-human factor B 
antibody was used to measure factor B levels in serum by radial immunodiffusion. T3 measurements in thyroidectomized animals 
or animals treated with PTU demonstrated a significant reduction in hormone levels compared to control. The results showed a 
reduction in AP lytic activity in rats treated with increasing amounts of T3 (1, 10, or 50 µg). Factor B activity was also decreased 
in the sera of hyperthyroid rats treated with 1 to 50 µg T3. Additionally, treating rats with 25 µg T3 significantly increased factor 
B levels in their sera (P < 0.01). In contrast, increased factor B concentration and activity (32%) were observed in hypothyroid 
rats. We conclude that alterations in thyroid hormone levels affect the activity of the AP and factor B, which may in turn affect 
the roles of AP and factor B in antibody production. 
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Complement consists of a group of serum and mem-
brane proteins that protect the organism against pathogens 
and modified-self components, functioning as a danger-
sensing and transmission system (1) in innate and adaptive 
immune responses. Complement activation through the 
classical (CP), lectin or alternative (AP) pathways converges 
at the formation of C3 convertase, leading to the cleavage 
and activation of the C3 component. The events following 
this activation culminate in the assembly of the membrane 
attack complex (MAC), which disrupts the membrane of 
the target cell and can lead to cell lysis (2). The fragments 
generated during the activation process have important 
biological functions, including facilitation of phagocytosis, 
clearance of immunocomplexes, inflammation, the immune 
response, and tissue homeostasis (3,4). Complement is 
an important link between innate and adaptive immunity, 
regulating both B and T cell responses by interacting with 
cell surface receptors. It is well known that complement frag-
ments function in antibody production by activating naive B 
cells, promoting the survival of B cells in germinal centers 
and functioning in the negative selection and maturation 
of self-reactive B cells (4). 
Previous studies have indicated that there is a con-
nection between the immune system and the hormones 
that regulate thyroid function (thyroid-stimulating hormone 
and thyrotropin-releasing hormone) (4-6). Additionally, the 
pathology of some thyroid diseases includes autoimmune 
processes (7). Hashimoto’s thyroiditis results from the body 
mistakenly recognizing normal thyroid cells as foreign tis-
sue and generating auto-antibodies against these cells. 
In Graves’ disease, an autoimmune hyperthyroidism, the 
body produces auto-antibodies that stimulate and attack the 
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thyroid, causing the gland to grow and overproduce thyroid 
hormones (8). The activation of the complement system 
(CS) in these autoimmune processes has been described. 
Deposition of the MAC occurs in thyroid cells in Graves’ and 
Hashimoto’s diseases. The altered expression of comple-
ment membrane regulators (CD46, CD55, and CD59) can 
affect the damage produced by complement fixation in these 
cells (9). Oleesky et al. (10) showed that plasma levels of 
C9 are increased in Graves’ disease and that treatment 
with anti-thyroid drugs decreases these levels. In a study 
of C6-deficient rabbits, it was suggested that the MAC is 
necessary for the development of fully expressed, severe 
experimental autoimmune thyroiditis and could be related 
to the pathogenesis of the disease (11). 
The possible connection between alterations in thyroid 
hormone levels, complement proteins and the events of 
the immune response that trigger autoimmune processes 
deserves further investigation. Studies evaluating comple-
ment activity in both normal physiological conditions and 
under conditions of altered levels of thyroid hormones 
might further our understanding of the role played by the 
CS in triggering autoimmune processes. Antibody produc-
tion against self components is one characteristic of these 
processes. Since the CS participates in antigen trapping 
within germinal centers and regulates multiple stages of 
the B cell response (12), it is possible that the effects of 
thyroid hormones on the CS might indirectly affect antibody 
production and the onset of autoimmune diseases. 
We observed that inducing hypothyroidism in rats by 
treatment with propylthiouracil (PTU) or by thyroidectomy 
increases the production of anti-sheep red blood cell anti-
bodies (13) and that treating rats with triiodothyronine (T3) 
decreases antibody production (14). An increase in AP 
lytic activity is observed in hypothyroidism, suggesting a 
relationship between complement and low levels of thyroid 
hormones (15). Additionally, it was shown that a deficiency 
in C4b-binding protein does not affect the development of 
systemic lupus erythematosus (16). The authors of the 
cited study suggested that the alternative pathway drives 
complement-dependent renal injury and indicated that this 
pathway may be related to the progression of autoimmune 
diseases. In light of this information, we sought to examine 
AP activity in rats suffering from hyperthyroidism induced 
by treatment with T3. In addition, as AP activity was altered, 
factor B activity was also evaluated in both hyperthyroid 
rats (treated with T3) and in rats rendered hypothyroid by 
PTU or thyroidectomy.
Material and Methods 
Animals and treatment
The animal breeding house of the Faculty of Pharma-
ceutical Sciences of Ribeirão Preto, University of São Paulo, 
supplied specific pathogen-free, young adult male Wistar 
rats weighing 180 ± 10 g. All treatment groups were main-
tained under identical conditions. During treatment, animals 
received food and water ad libitum. Three different strategies 
to alter the thyroid hormones in rats were used. 
The first group was treated with T3 from Purifarma® 
(Brazil). T3 was administered in a suspension consist-
ing of 0.5 g carboxymethylcellulose (CMC), 0.18 g ethyl 
4-hydroxybenzoate, 0.02 g propyl 4-hydroxybenzoate, and 
water in a final volume of 100 mL. Rats were divided into 
experimental and control groups and received 1 mL T3 (1.0 
to 50 µg) or 1 mL CMC suspension, respectively, by daily 
gavage for 7 or 12 days. 
To obtain rats with low levels of thyroid hormones, 
PTU tablets from Biolab-Searle® (Brazil) were powdered 
and resuspended in water. Two milliliters of suspension 
(5 mg·200 g body weight-1·day-1) or water (controls) was 
administered by gavage at timed intervals (8, 16, and 30 
days) to groups of approximately 8 rats each.
For thyroidectomy, adult rats weighing 180 g were 
anesthetized with an ip injection of 2.5% tribromoethanol 
in sterile saline solution (1 mL/200 g weight). Standard 
procedures were used for thyroidectomy. Briefly, a midline 
skin incision was made along the length of the neck. The 
underlying tissues were removed, and the salivary glands 
were retracted laterally. The two halves of the sternohyoid 
muscle were separated and retracted laterally. The thyroid 
muscle was separated from the lobes of the thyroid gland 
and retracted along with the sternohyoid muscle. A midline 
cut was made in the isthmus, and the thyroid glands were 
excised bilaterally. Extreme care was taken not to damage 
the laryngeal nerve. Sham (euthyroid/control)-operated 
animals underwent the same surgical procedures without 
removal of the thyroid gland. Rats were used for experi-
mentation 16 days after surgery.
In all procedures, the rats were euthanized according 
to criteria approved by the Ethics Committee for the Use of 
Animals (CEUA) of the Ribeirão Preto Campus, University of 
São Paulo (protocol No. 05.1.1160.53.9) 24 h after the end 
of each treatment and after 12 h of fasting. Blood samples 
were allowed to clot at room temperature for 1 h. Aliquoted 
serum was stored at -70°C until analysis.
Determination of serum concentrations of thyroid 
hormones
The concentrations of thyroid hormones [total T3 and 
total thyroxine (T4)] were measured using a competitive 
immunoassay with an enhanced chemiluminescence-end 
point (Immulite model 1000, DPC, USA). The Immulite 
analyzer, an instrument for solid-phase, two-site chemilumi-
nescent assay (DPC), was used for hormone measurement. 
Assay sensitivities were >1 µg/dL.
Evaluation of complement AP activity 
A hemolytic assay measuring the kinetics of lysis (17,18) 
was performed to evaluate AP lytic activity. This method is 
based on the determination of the time required for serum to 
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lyse 50% of an erythrocyte suspension (t1/2) under standard 
conditions. Triethanolamine (TEA) buffer (20 mM) contain-
ing 0.15 M NaCl, 0.8 mM azide, 8 mM ethyleneglycol-bis-
(β-aminoethyl ether) N,N,N’,N’-tetraacetic acid and 2 mM 
magnesium (TEA/EGTA/Mg2+), pH 7.2, was used for the 
assays. Rabbit erythrocytes were washed twice with TEA/
EGTA/Mg2+, and cell suspensions were standardized at an 
absorbance of 700 nm (approximately 10% erythrocytes). 
The rabbit erythrocyte suspension (100 µL) was added to 
200 µL of test serum diluted in TEA/EGTA/Mg2+, and the 
mixture was subsequently incubated at 37°C to measure 
the kinetics of lysis. 
Evaluation of factor B activity
Rat serum depleted of factor B (RB) was prepared 
(19,20) by heating a pool of sera at exactly 56°C. Every 
30 s, 60 µL serum was removed and transferred to tubes 
containing TEA-EGTA-Mg2+ and kept on ice. Subsequently, 
200 µL of the rabbit erythrocyte suspension was added, 
and the mixture was incubated at 37°C for 30 min. Cold 
PBS was added to stop the reaction, and the samples were 
then centrifuged for 10 min. The absorbance of the solution 
at 412 nm was measured, and the percent 
lysis was calculated in reference to the lysis 
of erythrocytes in water (set to 100%). The 
percent lysis was used to determine the 
residual AP activity. 
The residual AP activity was evaluated 
to determine the time necessary to selec-
tively inactivate factor B. RB was used to 
evaluate factor B activity in the serum of 
experimental and control animals using a 
modified Mayer’s method (21). Briefly, RB 
(60 µL) was added to 300 µL of test serum 
diluted 1:5 in TEA-EGTA-Mg2+. Samples 
were subsequently incubated with 200 µL 
rabbit erythrocyte suspension for 30 min 
at 37ºC. After incubation, 300 µL cold PBS 
was added, the samples were centrifuged 
and the absorbance of the supernatants was 
measured at 412 nm. The absorbance of cell 
supernatants lysed in water (100% lysis) or 
in RB without the addition of test serum (0% 
lysis) was measured as control.
Determination of the relative 
concentration of factor B
The relative concentration of factor B was 
determined by radial immunodiffusion (22) us-
ing rabbit anti-human factor B (Calbiochem, 
USA), which cross-reacts with rat factor B. 
The diameters of the precipitation halos were 
measured, and the values were expressed as 
a percentage of the halo diameter obtained 
from a pool of control rat sera. 
Statistical analysis 
Results for the control and treated animals were com-
pared by the Mann-Whitney test using the GraphPad Prism 
software version 3.0 for Windows (GraphPad Software, 
USA) (23). P values <0.05 were considered to be statisti-
cally significant.
Results
As expected, treating rats with T3 (25 µg) for 12 days 
(Figure 1A) increased the serum level of this hormone. 
The levels of T3 in the sera of both PTU-treated and 
control animals are reported in Figure 1B, which shows a 
significant decrease in T3 as a consequence of PTU treat-
ment. The serum concentration of T4 was also measured 
in T3-treated rats; however, we were unable to detect T4 
with the method employed in this study (sensitivity >1 µg/
dL). The AP lytic activity in the serum from rats treated 
with T3 was decreased (increased t1/2 values) compared 
to control (Figure 1C). A range of T3 doses (0.15 to 50 
µg) was evaluated and showed a dose-dependent effect 
(data not shown). Treating rats with PTU for 16 days led 
Figure 1. Treatment with triiodothyronine (T3) or propylthiouracil (PTU) alters the 
lytic activity of the alternative pathway. A, T3 levels detected in the sera of rats 
treated with either carboxymethylcellulose (CMC; controls) or 25 µg T3 suspen-
sion for 12 days. Each column indicates the mean ± SEM obtained for three inde-
pendent experiments at each time (N = 8); *P = 0.0043 compared to rats treated 
with CMC (controls; Mann-Whitney test). B, Effect of PTU treatment on the serum 
levels of T3 in rats treated with water (controls) or with 5 mg PTU suspension for 
16 days. Each column indicates the mean ± SEM obtained for three independent 
experiments at each time (N = 10); *P = 0.0001 compared to rats that received 
water (controls; Mann-Whitney test). C, Effect of T3 treatment on AP lytic activity 
(t1/2). Rats were treated with either CMC (controls) or 25 µg T3 suspension for 12 
days. Each column indicates the mean ± SEM obtained from t1/2 values (N = 8); 
*P = 0.0019 compared to rats treated with CMC (controls; Mann-Whitney test). D, 
Effect of PTU treatment on AP lytic activity. Rats were treated with water or 5 mg 
PTU suspension for 16 days. Each column indicates the mean ± SEM obtained 
from t1/2 values (N = 10); *P = 0.0286 compared to rats treated with CMC (con-
trols; Mann-Whitney test). 
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to a significant increase in AP lytic activity (decreased t1/2 
values, Figure 1D), corroborating a previous report (15). A 
range of PTU doses (1 to 25 mg·200 g body weight-1·day-1) 
was evaluated, showing that this effect was dependent on 
both the dose and the treatment period (data not shown). 
Similarly, T3 levels in thyroidectomized rats (Table 1) de-
creased over 4-fold compared to sham-operated animals, 
while AP lytic activity increased 30%.
Evaluation of factor B activity 
Prior to the experiments, RB was prepared as described 
in Material and Methods. RB is a serum depleted of factor 
B by heating. As shown in Figure 2A, heating the serum 
for 30 s resulted in a hemolysis rate of 65%, followed by 
a reduction of 30% after 30 additional seconds of heating, 
confirming that AP lytic activity decreased as heating times 
increased. Based on this result, we chose an incubation 
time of 180 s to demonstrate that the heating process was 
able to inactivate factor B. To restore factor B activity to the 
inactivated samples, we added purified human factor B at 
concentrations below, above and equivalent to the factor 
B concentration in human serum. The AP lytic activity was 
restored by the addition of purified human factor B, show-
ing that we efficiently produced RB samples by heating the 
serum to 56°C for 180 s (Figure 2B). Following this step, 
factor B activity was evaluated in sera from rats treated 
with thyroidectomy, PTU or T3. As observed in Figure 3, a 
reduction in the functional activity of factor B was observed 
in rats treated with increasing concentrations of T3 for 7 days 
(Figure 3A) or with 25 µg T3 for 12 days (Figure 3B).
Treating rats with PTU increased factor B activity (Figure 
4A). A similar result was also observed in thyroidectomized 
animals when compared to sham-operated controls (Table 
2). Treating rats with PTU to induce hypothyroidism in-
creased the serum concentration of factor B as indicated 
by a specific antibody using radial immunodiffusion (Figure 
4B).
Discussion
Previous results from our laboratory have shown that 
PTU-induced hypothyroidism in rats increases the produc-
tion of antibodies against sheep red blood cells (13) while hy- Figure 3. Treatment with triiodothyronine (T3) alters the func-
tional levels of factor B. A, Rats were treated with 1, 10 or 50 
µg T3 for 7 days, and factor B activity was evaluated using rat 
serum depleted of factor B (RB). The controls received carboxy-
methylcellulose (CMC). Each column indicates the mean ± SD of 
hemolysis (%) by RB added to sera from controls or experimental 
rats (N = 8), obtained for three independent experiments at each 
time; *P < 0.01 compared to rats treated with CMC (controls; 
ANOVA with the Dunnett test for multiple comparisons). B, Rats 
were treated with 25 µg T3 for 12 days and factor B activity was 
evaluated using RB. The controls received CMC. Each column 
indicates the mean ± SD of hemolysis (%) by RB added to sera 
from controls or experimental rats (N = 8), obtained for three in-
dependent experiments at each time; *P < 0.0001 compared to 
rats treated with CMC (controls; Mann-Whitney test).
Figure 2. Production and evaluation of rat sera depleted of fac-
tor B (RB). A, The inactivation of rat complement in serum was 
performed at 56°C. The alternative pathway (AP) lytic activity of 
a pool of normal rat sera decreased with increasing heating time 
(s). The points of the curve correspond to the mean ± SD values 
from duplicate experiments. B, AP lytic activity of a pool of normal 
rat serum inactivated at 56°C (RB) and incubated with different 
concentrations of purified human factor B to restore the lytic ac-
tivity. Values obtained for three independent experiments at each 
time. The lysis of sheep red blood cells in water was used as a 
control (100% lysis). 
Table 1. Serum levels of triiodothyronine (T3) and alternative 
pathway lytic activity (t1/2) in thyroidectomized (Tx) and sham-
operated (SO) rats.
T3 (ng/dL) t1/2 (min)
Tx 15.63 ± 4.93 (N = 10) 1.288 ± 0.32 (N = 12)
SO 65.51 ± 8.14 (N = 9) 1.865 ± 0.39 (N = 10)
Data are reported as the means ± SD for three independent ex-
periments.
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perthyroidism induced by T3 treatment decreases antibody 
production (14). Since the reference levels of serum T3 for 
humans, which were determined using the same method as 
employed in the present study (70-210 ng/dL), rats treated 
with T3 exhibited a significantly higher T3 level (~700 ng/dL) 
than untreated rats. Previous analysis of the CS in PTU or 
thyroidectomy-induced hypothyroidism has shown that the 
lytic activity of the AP (but not the CP) was significantly in-
creased in hypothyroid animals compared to control animals 
(15). Here, we confirm those data and further investigated 
AP lytic activity in rats with hyperthyroidism. In agreement 
with the results of PTU treatment or thyroidectomy, the 
CP was not affected by hyperthyroidism under our assay 
conditions (results not shown). However, the lytic activity 
of the AP, as evaluated by its capacity to lyse rabbit eryth-
rocytes, was dose- and time-dependently reduced. Under 
these conditions, T4 levels were decreased to undetectable 
values. These data corroborate our previous observations 
and show that the thyroid hormone T3 (and its precursor 
T4) affects the lytic potency of the CS. In an oversimplified 
view, it is possible that changes in the ability to generate CS 
fragments as a consequence of thyroid hormone alteration 
would correspond to an increased or decreased potential 
to generate an antibody response. Complement activation 
products generated from the CP interact with cell surface 
receptors to generate an antibody response (4). The pres-
ence of modified-self molecules capable of activating the 
AP in some of these situations could enhance or even initi-
ate this response. Complement fragments formed during 
CS activation bind to antigen-antibody complexes (ICs), 
facilitating IC trapping within germinal centers (12) and 
maintaining increased local concentrations of the antigen, 
thus decreasing the threshold for antibody production (1). 
Therefore, the effects of alterations in thyroid hormone levels 
on the production of anti-sheep red blood cell antibodies 
might be explained at least in part, by the effect of thyroid 
hormones on the CS. In addition, T3 affects DNA synthesis 
and antibody production by mouse lymphocytes in culture, 
and it is known that temporarily blocking thyroid function 
will depress antibody production (24). T3 might regulate B 
lymphocyte proliferation and antibody production in birds 
and mammals (6). Hassman et al. (25) reported that the 
development of an autoimmune response was suppressed 
in rats treated with a combination of T4 and thyroglobulin 
plus complete Freund’s adjuvant. 
In addition to the recognized involvement of the CS in 
the pathology of autoimmune thyroid disease (16,26), our 
observations, which were made in the absence of autoim-
mune processes, might be important for the understanding 
of the role of CS in triggering the development of these 
diseases. Factor B activity in the serum of thyroidectomized, 
PTU-treated or T3-treated rats was also investigated in 
the present study. Activated factor B (Bb fragment) is part 
of the membrane AP C3 convertase (C3bBb) that leads 
to the effective activation of the AP (27). Factor B activity, 
which we evaluated using a pool of factor B-deficient sera 
(RB), was also affected by alterations in thyroid hormone 
levels. Rats treated with PTU or submitted to thyroidectomy 
showed increased factor B activity, while rats treated with 
T3 showed decreased factor B activity. An anti-human fac-
tor B antibody that cross-reacts with rat factor B allowed 
us to measure the relative concentration of this protein by 
radial immunodiffusion in some of the serum samples from 
rats treated with PTU. In agreement with the increased 
factor B activity observed in the hemolytic assay employ-
ing RB, the results of the immunodiffusion assay showed 
that the concentration of factor B in sera obtained from 
hypothyroid rats was increased in comparison to a pool of 
normal rat sera. Unfortunately, the volume of cross-reacting 
antibody available was not sufficient to measure the factor 
Figure 4. Treatment with propylthiouracil (PTU) alters factor B ac-
tivity in rats. A, Effect of 16-day PTU treatment (5 mg·200 g body 
weight-1·day-1) on factor B activity, as evaluated by alternative 
pathway (AP) lytic activity. B, Factor B concentration in the sera 
of rats treated with PTU determined by a radial immunodiffusion 
assay using rabbit anti-human factor B (Calbiochem). The diam-
eters of the precipitation halos were measured and values are 
reported as the percentage of the halo diameter calculated from 
a pool of control rat sera. *P < 0.05 (ANOVA with the Dunnett test 
for multiple comparisons).
Table 2. Relative factor B activity in thyroi-
dectomized rats as determined by a hemo-
lytic assay employing serum deficient in 
factor B.
Assay Factor B activity (%)
1 35.54
2 46.05
3 70.21
4 13.64
5 57.65
6 62.36
7 12.37
8 33.95
Data are reported as percent of factor B 
activity in control animals (sham-operated, 
normal rats undergoing surgery on the 
same day). N = 16 (from a total of 8 differ-
ent assays, each using 2 rats).
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B concentration in serum samples from thyroidectomized 
and hyperthyroid rats. 
It is important to note that altered factor B activity is 
not necessarily associated with an altered concentration of 
factor B. Other components and regulators of complement 
at the level of factor B activation, such as properdin and 
factor I, might be affected by the levels of thyroid hormone. 
We also evaluated the activities of factor H and C3 in some 
serum samples from rats treated with PTU; however, under 
our assay conditions, we did not observe any alterations in 
the activity of these components (results not shown). 
To our knowledge, these are the first published data 
showing an effect of thyroid hormones on the activity of 
complement factor B. Thyroid hormones alter the expres-
sion, synthesis and activity of factor B. Further studies are 
necessary to understand how the concentration of thyroid 
hormones in serum could affect complement proteins. 
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